As such, there is great interest in FXR as a therapeutic target for treating chronic liver diseases, including cholestasis, cirrhosis, and nonalcoholic steatohepatitis (NASH) (3, 4, 18). The gene discussed is NR1H4; the disease is Cirrhosis.